Precision medicine for more oxygen (P4O2)-study design and first results of the long COVID-19 extension

Accepted/In Press date: 15 June 2023

Published date: July 2023

Additional Information: Funding Information: M.I. Abdel-Aziz has nothing to declare. N. Baalbaki has nothing to declare. S. Bazdar has nothing to declare. I. Beekers has nothing to declare. R.J.H.C.G. Beijers has nothing to declare. J.M. Blankestijn has nothing to declare. M. van de Berge has nothing to declare. J.J.P. van den Bergh has a research funding from UCB and Amgen (outside P4O2). L.D. Bloemsma has nothing to declare. H.J. Bogaard received a Grant support Ferrer (Janssen, MSD). C.D.C. Born has nothing to declare. M.S.G.M. Bracke is the Co-founder of Clear. M.E.B. Cornelissen has nothing to declare. J.W.F. Dagelet received personal fees from the start-up company Breathomix BV. A.M. van der Does has nothing to declare. G.S. Downward has nothing to declare. C.M. van Drunen has nothing to declare. J.W. Duitman will receive financial support from Boehringer and Abbvie for the P4O2 ILD cohort. D. Gach has nothing to declare. J. Garssen has nothing to declare. J.J.M. Geelhoed has nothing to declare. J. Glastra is employee at Quantib. K. Golebski has nothing to declare. I.H. Heijink has a Research grant from Boeheringer Ingelheim outside the scope of the submitted work. P.S. Hiemstra has nothing to declare. J.C.S. Holtjer has nothing to declare. S. Holverda has nothing to declare. L. Houweling has nothing to declare. J.J.L. Jacobs has nothing to declare. R. Jonker has nothing to declare. P.J.M. Kuks has nothing to declare. A.K.A.L. Kwee has nothing to declare. R.C.J. Langen has nothing to declare. A.H. Maitland-van der Zee has received research grants outside the submitted work from GSK, Boehringer Ingelheim, AbbVie and Vertex, she is the PI of P4O2 (Precision Medicine for more Oxygen), a public private partnership co-funded by Health~Holland involving many private partners that contribute in-cash and/or in-kind (Aparito, Boehringer Ingelheim, Breathomix, Clear, Danone Nutricia Research, Fluidda, MonitAir, Ncardia, Ortec Logiqcare, Philips, Quantib-U, RespiQ, Roche, Smartfish, SODAQ, Thirona, TopMD and Novartis), and she has served in advisory boards for AstraZeneca, GSK, and Boehringer Ingelheim with money paid to her institution. M.M.A. Van Melle is advisor and previous researcher in conquest and prevail research project, funded by Optimum Patient Care and AstraZeneca.P. Moeskops is employee at Quantib. F.A.A. Mohamed Hoesein has nothing to declare. J. Mosayebi Amroabadi has nothing to declare. L. Noij has nothing to declare. E.J. Nossent has speaker fees for lectures and educational events (Janssen, Bayer/MSD, Astra Zeneca) United Therapeutics/Ferrer, Boehringer Ingelheim B.V., Chiesi. J. Olsson is employed at Smartfish which produce Remune (which is used in P4O2 as oral nutrition product). J. Otker has nothing to declare. S.D. Pouwels has an affiliation. B.R. Rae has nothing to declare. L.B. Richards has nothing to declare. A. Rodriguez Ruiz has nothing to declare. D.W. Schaminee has nothing to declare. A.M.W.J. Schols has nothing to declare. L.T. Schuurman has nothing to declare. S. Shahbazi Khamas has nothing to declare. G. Slingers receives personal fees from the company Breathomix BV. M. Tamarit receives personal fees from the company Breathomix BV. G.F. Vasse has nothing to declare. I. Verkouter has nothing to declare. R. de Vries receives personal fees and has a substantial interest in the company Breathomix BV. Y. de Wit-van Wijck has nothing to declare. Funding Information: Partners in the Precision Medicine for more Oxygen (P4O2) consortium are the Amsterdam UMC, Leiden University Medical Center, Maastricht UMC+, Maastricht University, UMC Groningen, UMC Utrecht, Utrecht University, TNO, Aparito, Boehringer Ingelheim, Breathomix, Clear, Danone Nutricia Research, Fluidda, MonitAir, Ncardia, Ortec Logiqcare, Philips, Proefdiervrij, Quantib-U, RespiQ, Roche, Smartfish, SODAQ, Thirona, TopMD, Lung Alliance Netherlands (LAN) and the Lung Foundation Netherlands (Longfonds). The consortium is additionally funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health (LSHM20104; LSHM20068), to stimulate public-private partnerships and by Novartis. Publisher Copyright: © 2023 by the authors.

Keywords: infectious disease, long COVID, precision medicine, prospective observational cohort study

Local EPrints ID: 480665

URI: http://eprints.soton.ac.uk/id/eprint/480665

DOI: doi:10.3390/jpm13071060

ISSN: 2075-4426

PURE UUID: 38c1e82d-3b54-4501-9cab-c957b38e4845

ORCID for Paul J. Skipp: orcid.org/0000-0002-2995-2959

Date deposited: 08 Aug 2023 16:40

Last modified: 01 May 2024 01:34